Top Markets
Coin of the day
Hemostemix Inc. Hemostemix Inc.

Hemostemix Inc.

HEM
Rank in Stocks #32158
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Share Price
$0.05504527
Last synced: 2026-08-17
Market Cap
$10.89M
Change (1 day)
15.38%
Change (1 year)
-10.64%
Country
CA
Trade Hemostemix Inc. (HEM)

Category

Dividend history for Hemostemix Inc. (HEM)
Hemostemix Inc. (stock symbol: HEM) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Hemostemix Inc. (HEM) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH
0.00%
KR